Bladder Cancer

Immunogenic Cell Death Role in Urothelial Cancer Therapy.

Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost for treatment of all cancers. This scoping review clarifies the available evidence on the role of a novel therapeutic approach called immunogenic cell death (ICD) in urothelial cancer of the bladder.

Oncological and safety profiles in patients undergoing simultaneous TURB and TURP.

Evidence on the outcomes of simultaneous transurethral resection of bladder tumor (TURB) for bladder cancer and transurethral resection of the prostate (TURP) for obstructive benign prostatic hyperplasia is limited and contradictory.

Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms.

Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB.

Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.

The familial aggregation of bladder cancers has been observed, but the incidence and association of familial bladder cancer with germline pathogenic and likely pathogenic (P/LP) variants is unknown.

Impact of exercise on physical health status in bladder cancer patients.

There is a scarcity of data on the impact of behavioral habits, such as exercise, on physical health in patients with bladder cancer. We investigated the association of exercise on self-reported physical health status and examined the prevalence of bladder cancer patients with sedentary lifestyle.

Outcomes of radical cystectomy in pT4 bladder cancer frail patients: Α high-volume single center study.

This study aims to evaluate the effect of frailty in patients undergoing radical cystectomy (RC) for locally advanced bladder cancer.

In this retrospective, single center study we evaluated 51 patients with pT4 bladder cancer treated with radical cystectomy between 2016-2020.

BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients.

Cystoscopy is the gold standard for bladder cancer detection, but is costly, invasive and has imperfect diagnostic accuracy. We aimed to identify novel and accurate DNA methylation biomarkers for non-invasive detection of bladder cancer in urine, with the potential to reduce the number of cystoscopies among hematuria patients.

Radiomics Signature Using Manual Versus Automated Segmentation for Lymph Node Staging of Bladder Cancer.

Bladder cancer (BC) treatment algorithms depend on accurate tumor staging. To date, computed tomography (CT) is recommended for assessment of lymph node (LN) metastatic spread in muscle-invasive and high-risk BC.

Inter-reader reliability of the vesical imaging-reporting and data system (VI-RADS) for muscle-invasive bladder cancer: a systematic review and meta-analysis.

To evaluate the diagnostic agreement between readers in VI-RADS interpretation to detect muscle-invasive bladder cancer (MIBC) preoperatively, we conducted a systematic review and meta-analysis of the available data.

Immune Mechanisms and Molecular Therapeutic Strategies to Enhance Immunotherapy in Non-Muscle Invasive Bladder Cancer - Beyond the Abstract

Recent advances in the bladder-sparing treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) have spurred investigation into the molecular mechanisms of tumor escape, revealing the close relationship between the tumor immune microenvironment (TME) and BCG response. In this review, Chu and Pietzak synthesize the current clinical and molecular landscape of BCG unresponsive bladder cancer (Figure 1).
email news signup